Stocks to consider, my man

If you're lookin' for cheap stocks that might pay off here's a list to look at, my man. MYMAN is not recommending all these stocks. Some are obviously much better picks than others and some will perform well in the coming weeks while others listed here won't. I just want to provide a starting point for those who are lookin' for something new to invest in and are willing to take a risk. As always, do your own research and invest in what looks right to you, my man. Companies that MYMAN has invested in already are bolded:

Avvaa World Health Care Products, Inc (AVVH) 0.0084
Biophan Technologies, Inc. (BIPH) 0.0120
Cord Blood America, Inc (CBAI) 0.0099
CytoCore, Inc. (CYOE) 0.100
Identa Corp. (IDTA) 0.0055
Imaging Diagnostics Systems (IMDS) 0.0080
Ingen Technologies, Inc. (IGNT) 0.0041
Intraop Medical Corporation (IOPM) 0.0450
LIGATT Security International (LGTT) 0.0009
Lifeline Biotechs, Inc. (LLBO) 0.0058
Mobiclear Inc. (MOBI) 0.0026
Newport Digital Technologies, Inc. (NPDT) 0.0410
Power3 Medical Products, Inc. (PWRM) 0.110
SpectraScience, Inc. (SCIE) 0.450
Signature Devices, Inc. (SDVI) 0.0014
Solos Endoscopy, Inc. (SNDY) 0.0103
Vicor Technologies, Inc (VCRT) 0.950

Feel free share your comments or recommend stocks you like, my man.

RegeneRx jumps on positive preclinical study data, my man

RegeneRx jumps on positive preclinical study data

NEW YORK (AP) - Shares of RegeneRx Biopharmaceuticals Inc. surged to a new year high Tuesday after the company reported positive data from a preclinical study of its prospective multiple sclerosis treatment RGN-352.RegeneRx said the drug improved the recovery of nerve function when it was tested on animals.In afternoon trading, shares of the Bethesda, Md.-based company jumped 32 cents, or 39 percent, to $1.14. Earlier they traded as high as $1.95, eclipsing a previous 52-week high of $1.82 set in January. LINK

MYMAN got into RGN last month.

Tomorrow could be a big HTDS day, my man

We'll see: Hard to Treat Diseases (HTDS) obtains H1N1 license with China

SFDASHENZHEN, China, Sept. 29 - HTDS www.htdsmedical.com (HTDS) The issuer's China based operating subsidiary Mellow Hope through its exclusive business partner Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd has been granted H1N1 license on September 24, 2009 by SFDA (China Authority) http://eng.sfda.gov.cn/eng. Mellow Hope is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd for International marketing and sales...LINK

Is Cord Blood America for real, my man?

CBAI is showing some life, my man. All the way up to 0.0085

MYMAN f**ked-up on Vermillion, Inc. (VRMLQ), my man

If MYMAN has listened to his first instinct and got into VRMLQ he would driving home with these ladies instead of just lookin' at this damn photo.

MYMAN considered buyin' VRMLQ a few months ago but thought about it too much and stayed away because of concerns about Vermillion's financial health. VRMLQ is currently trading at $13.50 and it pains MYMAN to even think about this.

So what's the lesson here, my man? You gotta be willin' to take the risks, my man. OK, so what's next? Sometimes you can think much and you should just go by instinct.

What's a future VRMLQ? Maybe these are some candidates:

BIOMAGNETICS DIAGNOS (BMGP) 0.17
Biovest International, Inc. (BVTI) 0.45
Cell Robotics International Inc. (CRII) 0.0035
Imaging Diagnostic Systems, Inc. (IMDS) 0.0090
Longport, Inc. (LPTI) 0.0100
Wellstar International, Inc. (WLSI) 0.0002

You can think of anyone else, feel free to share, my man.

Take a look at Polaris International Holdings (PIHN), my man

0.0035 +0.0004 (12.90%)

Get into ASFX, my man.

Looking good, my man

Sign up for the FierceBiotech newsletter, my man

FierceBiotech is the biotech industry's daily monitor, with a special focus on clinical trials, biotech & pharma deals, FDA decisions, and key regulatory issues

Take a look at Ecotality, Inc. (OTC: ETLY), my man

From their website: ECOtality, Inc. headquartered in Scottsdale, Ariz., is a leader in clean electric transportation and storage technologies. Through innovation, acquisitions and strategic partnerships, ECOtality accelerates the market applicability of advanced electric technologies to replace carbon-based fuels. ECOtality is the parent company of Electric Transportation Engineering Corporation (eTec), Innergy Power Corporation and Fuel Cell Store.

Currently trading at 0.22

Some recent articles and press releases:

Electric Car-Charging Network Expands

Ecotality makes China deals

ECOtality sprints ahead with electric charge stations network

ECOtality’s eTec Awarded Patent for Bridge Power Manager

Have a nice weekend, my man

Bazirgani stocks, my man

MYMAN has a great respect for Bazirgani who posts on the Google finance boards. He helped convinced MYMAN to invest in HTDS and VRAL and today MYMAN invested in two more stocks that Bazirgani recommends: IMDS and SNDY.

Unfortunately, Bazirgani doesn't have a blog or a web site but you can find him on occasion on the Google message boards for HTDS, GETA and a few others. He consistently provides useful insight and he makes strong stock picks when it comes to investing in biotech stocks. The man does serious research. Stocks he has cited or invested in include ADLS, AVXT, CADX, CTIC, GETA, HTDS, IMDS, OLGX, SNDY. Bazirgani says OLGX, IMDS are both in category of 1000% rise within a year.

MYMAN agrees with Bazirgani: Do your research, be patient, don't sell early! He is not always right and no one is. But MYMAN recommends including Bazirgani as part of your research, my man.

CTIC pulls European marketing application for its lung drug Opaxio, my man

Not good news today but keep in mind that Pixantrone is the key drug for CTIC and if that gets approved next year by the FDA, CTIC is gonna soar. PATIENCE, my man: Link to article.

BioElectronics Making BIG News This Week (BIEL)

From September 15th but an interesting read:

BioElectronics Making BIG News This Week (BIEL)

The BioElectronics Corp (Public, OTC BIEL) has been making news this week, with the announcement of their schedule for filing with the U.S. Food and Drug Administration for 510 (K) pre-marketing clearance. It has also been announced the biotech company is a runner up in the 2009 Technology Innovation winners for their wearable drug-free patch using electromagnetic energy for pain relief.

BioElectronics is seeking clearance for their over the counter ActiPatch Therapy and Recovery RX products. In a statement by BioElectronics CEO Andrew Whelan the company is excited that they will soon begin the clinical study data, and usability studies for the product that is for the treatment of musculoskeletal complaints of pain. The ActiPatch that is for the pain relief of the heal and foot pain is also able to be used in painkilling treatment of postoperative edema, and superficial soft tissue treatment.

Whelan went on to state that they believe this will be a $100 million dollar annual market for the company in treating pain and the clinical data that has been collected by Dr. David G. Genecov is strong, showing it is 100 percent safe and effective. The BioElectronics CEO believes, along with the ActiPatch FDA clearance for other treatments will help the company to gain fast approval for the OTC clearance.

During the next few weeks Whelan states the corporation will file additional applications with the FDA for palliative treatment for postoperative edema and for pain in superficial tissue, which will allow them to market the product in the general surgical market. BioElectrionics plans for their clinical studies to end over the next few months

Poll results from last week: "Time to get out of HTDS?"

Yes	17 (22%)
No	46 (62%)
Unsure	11 (14%)

Med Gen Inc. (OTC:MDIN), a cheap gamble , my man

Currently at 0.0001

China Aoxing Pharmaceutical Company (CAXG.OB) received SFDA approval...

China Aoxing Pharmaceutical Company (CAXG.OB) received SFDA approval to begin a clinical trial of Tilidine/Naloxone capsules, a narcotic drug for moderate to severe pain (see story). The drug is given to alleviate cancer and post-surgical pain. China Aoxing plans to begin the clinical trial by the end of this year, and expects to receive final approval of the drug in 2011.

CAXG is currently tradin' at $1.30, my man

Seeking Alpha

ARTICLE: China Biotech Week in Review: SFDA Approvals All Around

Last week, people from both sides of the Pacific, all of them with an interest in China life science, came together for ChinaBio Day, which was held in San Francisco in conjunction with BioPharma America. Experts with partnership experience brought their expertise to the Panel Discussions, which we covered in detail. The panel subjects were: A Big Pharma Perspective on Leveraging China’s Resources (see story), the Impact of the Financial Crisis on China Partnering (see story), Case Studies of Successful Partnerships (see story), and Factors for Success in China Partnerships (see story).

Genzyme Corp. (NSDQ: GENZ), the third largest biotech company by revenue, began construction of a $100 million R&D center in Beijing (see story). The center, which will eventually employ 350 people, will comprise 200,000 square feet (18,580 square meters) and is expected to be completed in 2011. It will seek to discover and develop novel biologics and other gene therapies. Genzyme says it is interested in China because of the talent and the market.

Read the rest at Seeking Alpha

Stocks to keep an eye on this week, my man

CombinatoRx (CRXX) - FDA news on Wednesday, 9/23?
PPJ ENTERPRISE (PPJE) 0.0012 - Moving up. This was as high .25 back in May of 2008
RELM Holdings (RELM) - 0.0110 +0.0094 (587.50%) on Friday

Have a nice weekend, my man

Ain't no hard to treat disease here, my man

Consider CombinatoRx (NASDAQ:CRXX), my man

CombinatoRx has a nice pipeline

Currently trading at $2.22 and they are getting FDA committee review on 9/23. Check out what's being said on Stock Rants about them.

Viral Genetics (VRAL) is a long-term investment, my man

MYMAN recommends VRAL as a long-term investment, my man. Currently trading at 0.0680 and if you are willing to wait a year or more this may bring you the $$$. As always, do your own research, my man.

MYMAN hasn't heard back yet from the SFDA, my man

Not sure that if that's anything to worry about since they probably have gotten thousands of emails about HTDS, this week, my man. I have purchased more HTDS shares and will hold on.

Genta is soaring, my man

Remember Genta, my man? Just a few months ago Genta was a hot topic and was a sub-penny stock and then came the R/S. Then BIEL and HTDS started booming and it kind of seemed like Genta kind of fell off the radar and even MYMAN has to admit he kind of forget about Genta too.

But as of this moment Genta is trading at 0.935 and is up today +0.360 (62.61%). Props to all those to held on to Genta.

The autobiography of MYMAN

Consider Lifeline Biotechs (LLBO), my man

Currently trading at 0.0050 +0.0024 (92.31%) today.

HTDS update, my man

Yesterday I emailed the State Food and Drug Administration (SFDA) at inquires@sda.gov.cn in China asking them to confirmed information stated in the September 14th press release by HTDS. I got the following response, my man:

Please contact the Department of Drug Registration of SFDA
Phone: 86-10-88331203 88331213
E-mail: zhucs@sda.gov.cn

Best wishes

2009-09-16

Not very informative but at least they did get back to MYMAN. I sent another email to the new email address and I haven't heard back as of yet. I still don't see anything on the SFDA site mentioning HTDS or Mellow Hope.

But for the most part, I feel better about HTDS, my man. The stock didn't tank as I feared it might and it actually rallied a bit today. I haven't sold and will continue to hold and watch HTDS, my man.

HTDS

Looking good, my man: 0.0145 +0.0006 (4.32%)

Moving up so far today, my man

Cross Atlantic Commodities, Inc. (CXAC: OTC)
Genta (GETA)
Imaging3, Inc. (IMGG: OTCBB)
Lifeline Biotechnologies, Inc. (LLBO: OTC)

Helps with the HTDS stress, my man.

Boring Hemispherx BioPharma shows some life, my man

Some interesting news that should be of interest to us HEBers:

Hemispherx Board of Directors Authorizes Multimillion Dollar Expansion of Its FDA Licensed Manufacturing FacilitiesIncreases Capability to Expand Alferon LDO(TM) and Ampligen(R) for Various Influenza-Based Clinical and Commercial Production

PHILADELPHIA, Sep 16, 2009 (GlobeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") today announced that its Board of Directors has just approved up to $4.4 Million (U.S.) for full engineering studies, capital improvements, system upgrades, and introduction of building management systems to enhance production of three products: Alferon N(R) (its FDA licensed biologic), Alferon LDO and Ampligen(R). Alferon LDO and Ampligen(R) (Poly I : Poly C12U) are experimental therapeutics being developed for multiple clinical indications including prevention, prophylaxis and treatment of both seasonal and pandemic influenza. LINK

FDA approval finally coming, my man???

Genta closing in on Fifty Cent , my man

Genta now at 0.46

HTDS

Good luck to us all, my man.

Take a look at Provectus Pharmaceuticals (OTC: PVCT), my man

StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT). They have one of the deepest pipelines of any small cap biotech, focusing on treatments for: Melanoma, Psoriasis, Atopic Dermatitis, Breast Cancer, and Liver Metastasis. With three drugs nearly ready to enter Phase III, including one nearly entering Phase II for Breast Cancer.

Currently trading at 0.92

Contact the State Food and Drug Administration (SFDA) in China, my man

If you are invested in HTDS, please contact the State Food and Drug Administration (SFDA) and try to get confirmation of the September 14, 2009 press release from HTDS.

SHENZHEN, China, Sept. 14 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com
The Company is pleased to provide the following update to its shareholders and
followers on the (H1N1) Vaccine for Mellow Hope Inc, its China based
subsidiary and other general business matters.

At the beginning of September, Mellow Hope completed the clinical trial of
Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical
approval from the State Food and Drug Administration (SFDA)
http://eng.sfda.gov.cn/eng. Production will be started shortly.

Is this true?

I'm not seeing anything about it on the SFDA site or anywhere else.

State Food and Drug Administration (SFDA)
Address: A38, Beilishi Road, Beijing 100810, P.R. China
Fax: 86-010-68310909
Email: inquires@sda.gov.cn

HTDS is listed as "Caveat Emptor" on PinkSheets.com, my man

I suspect this has to with the hype and bashing of HTDS, not so much about HTDS itself, my man. But I'd like to hear from other people about this: http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds#getQuote

Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production

Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production

SHENZHEN, China, Sept 14, 2009 /PRNewswire-FirstCall via COMTEX/ -- HTDS www.htdsmedical.com The Company is pleased to provide the following update to its shareholders and followers on the (H1N1) Vaccine for Mellow Hope Inc, its China based subsidiary and other general business matters. At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly. LINK

HTDS up and away, my man

0.0210 +0.0126 (150.00%)

Participation in government tender of 7 million doses of H1N1 flu vaccine.

With the new H1N1 virus continuing to cause illness, hospitalizations and deaths in the whole world, it is highly recommended to make prepartaion for a voluntary H1N1 vaccination. Mellow Hope is the only one H1N1 vaccine supplier for the overseas market.

Right now, the clinical trial is being processed, it will be finished by this September and the manufacturing license will be released by this October.

In August of 2009, Mellow Hope will participate in a tender for supplying 6 million doses of H1N1 Flu Vaccine to Chile and another tender for supplying 1 million doses of H1N1 flu vaccine to Thailand. And the business opportunities with some other countires are being negotiated.

At the end of August, Mr. Terry Yuan, the President of Mellow Hope will visit Chile to discuss further for supplying H1N1 flu vaccine and other business opportunities in Latin American countries.

From the Shenzhen Mellow Hope Pharm Industrial Co site

What's being said about HTDS, my man

MYMAN still believes in HTDS and that we'll see this stock in the 0.05 to 0.10 cent range by the end of the year. Here are some articles and blog posts about HTDS that you may find of interest, my man:

"The fact of the matter is that HTDS is a pretty safe company. While it has experienced some unusually high volatility in recent weeks, its consistent stability over the past several years should, for the most part, put investors' minds at ease. While it has been extremely volatile in August thus far, fluctuating from very large gains/losses to miniscule ones, it is fairly certain that a new support level has been formed out of it."

http://investmentessentials.blogspot.com/2009/08/htds-stock-review.html


"Keep an eye on her the next few weeks. HTDS could very well breakout in a big way."

http://stockbb.net/2009/08/27/htds-another-12-gain-today

"What I find compelling is that HTDS has done some very astute things (acquisition of Mellow Hope) and appears to be very cost efficient in searching for new products. I will be very interested to see what kind of numbers Mellow Hope can produce for the company going forward. The Serbian operation holds out great hope for the company, too. It is working on modifications to a number of existing drugs to treat some of the more “popular” diseases of today’s society. Working with existing drugs also means that the dreaded FDA turndown is less likely and drugs can be brought to market quicker."

http://www.microstockprofit.com/2009/08/24/hard-to-get-a-read-on-htds

"Shenzhen Mellow Hope Pharm Industrial Co., a subsidiary of Hard to Treat Diseases [Pink Sheets: HTDS], has reached an agreement to be the sole international distributor of a Recombinant Hepatitis B vaccine manufactured by North China Pharmaceutical Group (see story). NCPC is a large state-owned pharmaceutical company, with a specialty in vaccines."

http://seekingalpha.com/article/156355-china-biotech-in-review-the-business-of-china-life-science

Stocks to consider next week, my man

Not saying you should buy these but they might be worth a look if you're looking for something new to invest in, my man:

Aventura Holdings, Inc. (OTC:AVNT) 0.0006 +0.0002 (50.00%)

Birch Mountain Resources Ltd. (OTC:BHMNF) 0.0280 +0.0223 (391.23%)

FINAVERA RENEWABLES INC (PINK:FNVRF) +0.0149 (40.82%)

Global General Technologies Inc (OTC:GLGT) 0.0083 +0.0017 (25.76%)

Gulf Coast Oil & Gas, Inc. (OTC:GCOG) 0.0018 +0.0008 (80.00%)

Rockelle Corp. (OTC:RKLC) 0.0013 +0.0006 (85.71%)

UNIVERSAL BIOENERGY INC (PINK:UBRG) 0.117 -0.013 (-10.00%)

BIEL moving up, my man

0.111

Insiders sell like there's no tomorrow, my man

Corporate officers and directors were buying stock when the market hit bottom. What does it say that they're selling now?

By Colin Barr, senior writer

Last Updated: September 11, 2009: 7:27 AM ET

NEW YORK (Fortune) -- Can hundreds of stock-selling insiders be wrong? The stock market has mounted an historic rally since it hit a low in March. The S&P 500 is up 55%, as U.S. job losses have slowed and credit markets have stabilized. But against that improving backdrop, one indicator has turned distinctly bearish: Corporate officers and directors have been selling shares at a pace last seen just before the onset of the subprime malaise two years ago. While a wave of insider selling doesn't necessarily foretell a stock market downturn, it suggests that those with the first read on business trends don't believe current stock prices are justified by economic fundamentals. "It's not a very complicated story," said Charles Biderman, who runs market research firm Trim Tabs. "Insiders know better than you and me. If prices are too high, they sell."

Link

God Bless America, my man

9/11

Never forget.

Stay with HTDS, my man

Do not give up on HTDS, my man.

Take a look at GenVec, Inc., my man

GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic, wfor the treatment of various cancers, including esophageal cancer, rectal cancer, and head and neck cancer. Currently trading at 0.776

Check out NeoPharm, my man

NeoPharm has been quietly and gradually climbing up, my man. NEOL was 0.07 back in February and is now at 0.270.

Update on Guangzhou Global Telecom, my man

I recently mentioned Guangzhou Global Telecom (GZGT.OB) as a "speculative pick" and I want to share this link to an item about GZGT on Seeking Alpha so that all my little man's can be better informed about this stock and make their choices, my man. Click here, my man.

China Kangtai Cactus Biotech, Inc. (OTC: CKGT ), my man

Currently trading at $1.40: China Kangtai Cactus Biotech, Inc. is a leading grower, developer, producer, and marketer of cactus-derived products, including nutraceuticals, nutritious food, health and energy drinks, beer, wine and liquor, extracts and powders, and animal feed. China Kangtai controls over 387 acres of plants and maintains an active R&D group that holds 18 product patents and is seeking another 12. China Kangtai's high-quality "green" products are sold throughout China via a distribution network that covers 12 of China's 23 provinces and two of China's four municipalities.

Stocks to consider this week, my man

MYMAN isn't sayin' you should buy these but they are cheap right now and may move up in the near future. Take a look at these:

AGEL
ARIO
CENC
CXAC
ENCS
EVFL
EKII
EWKS
GSPI
INCL
MOBI
MPTO
MXGD
SOFN
VTSI
WLSI

Have a nice weekend, my man

Consider Cross Atlantic Commodities (OTC:CXAC), my man

0.0003 +0.0001 (50.00%)

Cross Atlantic Commodities, Inc. imports and delivers coffee and coffee related products to customers located in the United States, Europe and Asia. During the year ended December 31, 2007, the Company continued to focus its efforts in the coffee business, as well as the food packaging consulting business. The Company also focused its efforts on marketing a variety of food products to wholesale retail chains throughout North America. In March 2008, the Company announced the launch of their division, Import Foods Division.

MYMAN gives props to Chris Moneymaker for pointing this one out to my man.

Final MOBI numbers for today, my man

0.0085

+0.0071 (507.14%)

MYMAN got at 0.0036 today with 125,000 shares. Damn, he wishes he got more.

Question is, what happens tomorrow with MOBI???

MOBI, my man

MOBI now at 0.0080
+0.0066 (471.43%)

MobiClear, Inc. (OTC:MOBI), my man

0.0030 +0.0016 (114.29%)

Mobiclear Inc. is a development-stage company engaged in providing electronic personal identity verification (PIV) solutions in connection with credit/debit card and Internet login transactions. The Company’s multiple gateway solution offers security in all forms of electronic business environments, including Internet shopping, business-to-business procurement transactions and retail shopping with credit/debit cards. In addition, its identification service ensures trade over the Internet, which in turn promotes both e-trade and invoice payment online. On September 18, 2008, the Company acquired approximately 67% interest in Mobiclear, Inc.